Phase 1 trial of Anti-CD47 Antibody in Haematologic Malignancies (NCT02678338) Phase 1b trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies (NCT03248479). The gene discussed is CD47; the disease is hematologic disorder.